CR
European regulators reportedly plan to seek more information from drugmakers such as Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) as part of an investigation into whether certain diabetes and weight-loss drug could be triggering suicidal thoughts in some users.
The European Medicines Agency began the review in July after receiving at least 170 reports about suspected adverse events involving the drugs. The EMA’s Pharmacovigilance Risk Assessment Committee met this week to discuss the matter. It plans to take up the topic again at a meeting in April, according to Reuters.
“While at this point no conclusion can be drawn on causal association, there are several issues that still need to be clarified,” the EMA said in a statement cited by Reuters.
The review has focused on GLP-1 receptor agonists, a group of medications that includes Novo Nordisk’s Rybelsus, Saxenda, Wegovy and Ozempic; Lilly’s Trulicity; AstraZeneca’s (NASDAQ:AZN) Bydureon and Byetta; and Sanofi’s (NASDAQ:SNY) Suliqua. It does not, however, include Lilly’s Mounjaro and Zepound, which belong to a different molecule class, Reuters said.